Výsledky vyhledávání

Akademický článek

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Autor: Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: eunice.wang@roswellpark.org., Issa GC; MD Anderson Cancer Center, Houston, TX, USA., Erba HP; Duke Cancer Institute, Durham, NC, USA., Altman JK; Northwestern University-Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., DeBotton S; Institut Gustave Roussy Service d'Hématologie Clinique, Paris, France., Walter RB; Fred Hutchinson Cancer Center, Seattle, WA, USA., Pettit K; University of Michigan, Ann Arbor, MI, USA., Savona MR; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Shah MV; Mayo Clinic, Rochester, MN, USA., Kremyanskaya M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Foran JM; Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA., Schiller G; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Adès L; Hôpital Saint-Louis (AP-HP) and Université Paris Cité and Centre d'Investigations Cliniques-Inserm CIC-1427, Paris, France., Heiblig M; Centre Hospitalier Lyon Sud, Lyon, France., Berthon C; Centre Hospitalo-Universitaire Lille, Lille, France., Peterlin P; CHU de Nantes-Hôtel-Dieu, Nantes, France., Rodríguez-Arbolí E; Department of Hematology, Hospital Universitario Virgen del Rocío, Seville Biomedicine Institute (IBiS/CSIC), University of Seville, Seville, Spain., Salamero O; Servei d'Hematologia de l'Hospital Vall d'Hebron i Unitat d'Hematología Experimental del Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Patnaik MM; Mayo Clinic, Rochester, MN, USA., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Grembecka J; University of Michigan, Ann Arbor, MI, USA., Cierpicki T; University of Michigan, Ann Arbor, MI, USA., Clegg B; University of Michigan, Ann Arbor, MI, USA., Ray J; University of Michigan, Ann Arbor, MI, USA., Linhares BM; University of Michigan, Ann Arbor, MI, USA., Nie K; Kura Oncology, Inc, San Diego, CA, USA., Mitra A; Kura Oncology, Inc, San Diego, CA, USA., Ahsan JM; Kura Oncology, Inc, San Diego, CA, USA., Tabachri M; Kura Oncology, Inc, San Diego, CA, USA., Soifer HS; Kura Oncology, Inc, San Diego, CA, USA., Corum D; Kura Oncology, Inc, San Diego, CA, USA., Leoni M; Kura Oncology, Inc, San Diego, CA, USA., Dale S; Kura Oncology, Inc, San Diego, CA, USA., Fathi AT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. 1310-1324.

Zobrazit plný text záznamu

Akademický článek

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.

Autor: Smith AE; Kura Oncology, Inc., San Diego, California., Chan S; Kura Oncology, Inc., San Diego, California., Wang Z; Moores Cancer Center, University of California San Diego, La Jolla, California., McCloskey A; Kura Oncology, Inc., San Diego, California., Reilly Q; Kura Oncology, Inc., San Diego, California., Wang JZ; Kura Oncology, Inc., San Diego, California., Patel HV; Kura Oncology, Inc., San Diego, California., Koshizuka K; Moores Cancer Center, University of California San Diego, La Jolla, California., Soifer HS; Kura Oncology, Inc., San Diego, California., Kessler L; Kura Oncology, Inc., San Diego, California., Dayoub A; Kura Oncology, Inc., Boston, Massachusetts., Villaflor V; City of Hope Comprehensive Cancer Center, Duarte, California., Adkins DR; Washington University at St. Louis, St. Louis, Missouri., Bruce JY; Wisconsin University, Madison, Wisconsin., Ho AL; Memorial Sloan Kettering Cancer Center, New York, New York., Perez CA; Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida., Hanna GJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Gascó Hernández A; Kura Oncology, Inc., Boston, Massachusetts., Saunders A; Kura Oncology, Inc., Boston, Massachusetts., Dale S; Kura Oncology, Inc., Boston, Massachusetts., Gutkind JS; Moores Cancer Center, University of California San Diego, La Jolla, California.; Department of Pharmacology, University of California San Diego, La Jolla, California., Burrows F; Kura Oncology, Inc., San Diego, California., Malik S; Kura Oncology, Inc., San Diego, California.

Publikováno v: Cancer research [Cancer Res] 2023 Oct 02; Vol. 83 (19), pp. 3252-3263.

Zobrazit plný text záznamu

Akademický článek

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.

Autor: Lassman AB; Division of Neuro-Oncology, Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New York., Sepúlveda-Sánchez JM; Hospital Universitario 12 De Octubre, Madrid, Spain., Cloughesy TF; University of California at Los Angeles, Los Angeles, California., Gil-Gil MJ; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain., Puduvalli VK; Division of Neuro-Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio., Raizer JJ; Northwestern University, Department of Neurology, Section of Neuro-Oncology, Chicago, Illinois., De Vos FYF; Department Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Butowski NA; University of California San Francisco, San Francisco, California., Clement PMJ; Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Groves MD; Texas Oncology PA, Austin, Texas., Belda-Iniesta C; Hospital Universitario HM Sanchinarro, Madrid, Spain., Giglio P; Division of Neuro-Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio., Soifer HS; QED Therapeutics, San Francisco, California., Rowsey S; QED Therapeutics, San Francisco, California., Xu C; QED Therapeutics, San Francisco, California., Avogadri F; QED Therapeutics, San Francisco, California., Wei G; QED Therapeutics, San Francisco, California., Moran S; QED Therapeutics, San Francisco, California., Roth P; Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 01; Vol. 28 (11), pp. 2270-2277.

Zobrazit plný text záznamu

Akademický článek

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

Autor: Javle M; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mjavle@mdanderson.org., Roychowdhury S; James Cancer Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Kelley RK; Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Sadeghi S; Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Macarulla T; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Weiss KH; Internal Medicine, Salem Medical Center, Heidelberg, Germany; Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany., Waldschmidt DT; Clinic for Gastroenterologie and Hepatologie, Klinikum der Universität zu Köln, Cologne, Germany., Goyal L; Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Borbath I; Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium., El-Khoueiry A; Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA., Borad MJ; Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA., Yong WP; National University Cancer Institute Singapore, National University Health System, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore., Philip PA; Karmanos Cancer Institute, Detroit, MI, USA., Bitzer M; Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany; Center for Personalized Medicine, Eberhard-Karls University, Tübingen, Germany., Tanasanvimon S; Internal Medicine, Chulalongkorn University, Bangkok, Thailand., Li A; Biostatistics and Data Management, QED Therapeutics, San Francisco, CA, USA., Pande A; Clinical Development, QED Therapeutics, San Francisco, CA, USA., Soifer HS; Translational Medicine, QED Therapeutics, San Francisco, CA, USA., Shepherd SP; Clinical Development, QED Therapeutics, San Francisco, CA, USA., Moran S; Clinical Development, QED Therapeutics, San Francisco, CA, USA., Zhu AX; Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Bekaii-Saab TS; Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, AZ, USA., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Oct; Vol. 6 (10), pp. 803-815. Date of Electronic Publication: 2021 Aug 03.

Zobrazit plný text záznamu

Akademický článek

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay.

Autor: Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Overman M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Poage GM; Biotheranostics, Inc., San Diego, California, USA., Soifer HS; Biotheranostics, Inc., San Diego, California, USA., Schnabel CA; Biotheranostics, Inc., San Diego, California, USA., Varadhachary GR; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: The oncologist [Oncologist] 2020 Nov; Vol. 25 (11), pp. e1807-e1811. Date of Electronic Publication: 2020 Sep 23.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání